Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183040 · ClinicalTrials.gov registry record · Phase 2
HORMA: Hormonal Regulators of Muscle and Metabolism in Aging
A Phase 2 study of Frailty and Sarcopenia, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 2
- Study locations
NCT00183040: Completed Phase 2 study of Frailty and Sarcopenia, sponsored by National Institute on Aging (NIA).
NCT00183040 is a Phase 2 study of Frailty and Sarcopenia that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 108 participants, below the 1,504-participant average among 48 other Frailty trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00183040, a Phase 2 study of Frailty and Sarcopenia, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the relationship of deficiencies in testosterone and growth hormone to loss of muscle mass (sarcopenia) and functional impairment during aging and whether there is an interaction of these two hormone systems in maintaining normal skeletal muscle mass and physical function.
Conditions Studied
Interventions
- DRUG Recombinant human growth hormone
- DRUG Topical testosterone
Study Locations (2)
Massachusetts
- Tufts University - Boston
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2002-09 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00183040 record still lists
NCT00183040 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 1,504-participant average among 48 other Frailty trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Frailty appearing as the primary indexed condition, and to 2 interventions - of which Recombinant human growth hormone is the first listed.
NCT00183040 reports a single indexed study location in Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT00183040 about?
NCT00183040 is a clinical study titled "HORMA: Hormonal Regulators of Muscle and Metabolism in Aging". The purpose of this study is to determine the relationship of deficiencies in testosterone and growth hormone to loss of muscle mass (sarcopenia) and functional impairment during aging and whether there is an interaction of these two hormone systems in maintaining normal skeletal muscle mass and phy...
What is the current status of trial NCT00183040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2002-09. Estimated completion is 2007-02.
What conditions does trial NCT00183040 study?
This clinical trial studies the following conditions: Frailty, Sarcopenia, Muscle Weakness.
What interventions are being tested in trial NCT00183040?
The interventions under investigation include: Recombinant human growth hormone (DRUG), Topical testosterone (DRUG).
Who is sponsoring clinical trial NCT00183040?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00183040 being conducted?
This trial has 2 study locations across Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Frailty
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00183040's enrollment target sits among peer trials
108 16th of 48 higher than 33 of 48 other Frailty trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Frailty trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Physical Ability and Cellular Senescence Elimination in HIV
RECRUITING · Phase 2
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
-
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
RECRUITING · Phase 2
-
An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia